[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100558265":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":34,"locations":39,"responsibleParty":55,"collaborators":57,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":66,"sex":72,"minAge":73,"maxAge":10,"enrollmentInfo":74,"targetDuration":10,"studyType":77,"phases":10,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":42,"whyStopped":10,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Gruppo Oncologico Italiano di Ricerca Clinica","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group A: long-lasting responders",null,"Patient long-lasting responders (PFS ≥9 months) to cabozantinib",[13],"Drug: Cabozantinib",{"label":15,"type":10,"description":16,"interventionNames":17},"Group B: primary refractories","Patient progressed from the start to cabozantinib therapy within 3 months",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"DRUG","Cabozantinib","Patients must have been treated with cabozantinib after one or more previous therapies for mRCC, as per clinical practise.",[9,15],[25,29,32],{"name":26,"affiliation":27,"role":28},"Carmine Pinto, MD","AUSL\u002FIRCCS of Reggio Emilia","PRINCIPAL_INVESTIGATOR",{"name":30,"affiliation":27,"role":31},"Cristina Masini, MD","STUDY_CHAIR",{"name":33,"affiliation":27,"role":31},"Stefania Di Girolamo, MD",[35],{"name":26,"role":36,"phone":37,"phoneExt":10,"email":38},"CONTACT","+39 0522296614","carmine.pinto@ausl.re.it",[40],{"facility":41,"status":42,"city":43,"state":10,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"AUSL-IRCCS of Reggio Emilia","RECRUITING","Reggio Emilia","42123","Italy","IT",{"type":48,"coordinates":49},"Point",[50,51],10.63125,44.69825,{"lat":51,"lon":50},[54],{"name":26,"role":36,"phone":37,"phoneExt":10,"email":38},{"type":56,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[58,61],{"name":59,"class":60},"Yghea","UNKNOWN",{"name":62,"class":63},"Ipsen","INDUSTRY","100558265","retrospective-analysis-of-patients-with-metastatic-renal-cell-carcinoma-treated-with-cabozantinib-100558265",false,"NCT06548867","Retrospective Analysis of Patients With Metastatic Renal Cell Carcinoma Treated With CABOzantinib","Retrospective Analysis of Patients With Metastatic Renal Cell Carcinoma Treated With CABOzantinib: a GENomic Signature for Describing Long-lasting Response","CABOGEN","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Patients with histological diagnosis of predominantly clear cell carcinoma\n* Availability of the tumor tissue from the primary tumor and\u002For a metastatic site for the genomic profiling analysis not older than 5 years.\n* Evaluable disease according to RECIST criteria v 1.1\n* Treatment with cabozantinib after one or more previous therapies for mRCC\n* Patient progressed from the start to cabozantinib therapy within 3 months or after 9 months\n* Any prognosis group according to the IMDC risk score\n* Signed informed consent must be obtained for living patients. Patients who died and patient untraceable will be analyzed based on the Authorization no. 9\u002F2016 of the Italian Data Protector Supervisor.\n\nExclusion Criteria:\n\n* Non-availability of tumor tissue from the primary tumor or a metastatic site for biomarker analysis\n* Patient progressed between 3 and 9 months from the beginning of treatment with cabozantinib.\n* Non-availability of clinical information useful to evaluate the IMDC risk group at baseline.","ALL","18 Years",{"count":75,"type":76},80,"ESTIMATED","OBSERVATIONAL","CABOGEN is a Observational, retrospective, multicenter study that will enroll patients with metastatic clear cell renal carcinoma (mccRCC) treated with cabozantinib after one or more previous lines of treatment that included TKIs, immune checkpoint inhibitors or mTOR inhibitors.",[80],"Metastatic Renal Cell Carcinoma",[80,82,83,84],"Genomic signature","long lasting response","cabozantinib treatment","2024-08-08",{"date":87,"type":88},"2024-08-12","ACTUAL",{"date":90,"type":88},"2024-05-28",{"date":92,"type":76},"2025-06-30",{"name":5,"class":6},1]